ArticleEuropean journal of nuclear medicine and molecular imaging2023
Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project.
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Dose-activity relationship in [Annals of nuclear medicine · 2026Article
- Optimal timing of post-therapeutic [BMC medical imaging · 2026Review
- Radioiodine-induced cGAS-STING signaling and antitumor immunity in thyroid cancer.Frontiers in immunology · 2026Review
- Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer.European thyroid journal · 2025Observational
- External validation of a predictive model for post-treatment persistent disease byEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Whole-body effective half-life of radioiodine in children and young adults with papillary thyroid cancer.Endocrine · 2025Article
- Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells.Theranostics · 2025Article
- Modelling the In Vivo and Ex Vivo DNA Damage Response after Internal Irradiation of Blood from Patients with Thyroid Cancer.International journal of molecular sciences · 2024Article
- New opportunities for dosimetric approach in patients with differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2024Article
- On the use of solidEJNMMI physics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 4 countries.
Funding
Abstract
purposeDosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[
methodsPatients were enrolled in four centres and administered fixed activities of 1.1 or 3.7 GBq of Na[
resultsOne hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16 mGy/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7 GBq were 0.05 Gy and 0.16 Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04 mGy/MBq were calculated for centre 1, 2, 3 and 4, respectively.
conclusionsA wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.